Cell cycle progression is monitored constantly to ensure faithful passage of genetic codes and genome stability. We have demonstrated previously that, upon DNA damage, TTK/hMps1 activates the checkpoint kinase CHK2 by phosphorylating CHK2 at Thr68. However, it remains to be determined whether and how TTK/hMps1 responds to DNA damage. In this report, we present evidence that TTK/hMps1 can be induced by DNA damage in normal human fibroblasts. Interestingly, the induction depends on CHK2 because CHK2-targeting small interfering RNA or a CHK2 inhibitor abolishes the increase. Such induction is mediated through phosphorylation of TTK/hMps1 at Thr288 by CHK2 and requires the CHK2 SQ/TQ cluster domain/forkhead-associated domain. In cells, TTK/ hMps1 phosphorylation at Thr288 is induced by DNA damage and forms nuclear foci, which colocalize partially with c-H2AX. Reexpression of TTK/hMps1 T288A mutant in TTK/hMps1-knockdown cells causes a defect in G 2 /M arrest, suggesting that phosphorylation at this site participates in the proper checkpoint execution. Our study uncovered a regulatory loop between TTK/hMps1 and CHK2 whereby DNA damage-activated CHK2 may facilitate the stabilization of TTK/hMps1, therefore maintaining the checkpoint control.
Introduction
Genome stability is maintained through an intricate network of signaling pathways, notably cell cycle checkpoints, which delay or stop the progression of the cell cycle in the event of DNA damage or replication block. Many proteins are involved, and these form cascades of signaling networks, mostly through phosphorylation and dephosphorylation. These proteins include damage recognition sensors, adapters or mediators, signal transducers and effectors that mediate cellular responses such as growth arrest, DNA repair or apoptosis (Branzei and Foiani, 2005; Niida and Nakanishi, 2006; Bartek and Lukas, 2007) .
One of the effector kinases is CHK2, a mammalian homolog of the budding yeast (Saccharomyces cerevisiae) Rad53 and the fission yeast (Schizosaccharomyces pombe) Cds1 (Allen et al., 1994; Murakami and Okayama, 1995; Antoni et al., 2007) . In yeast, Rad53 is activated by both DNA damage and replication block, whereas Cds1 functions mainly in the replication checkpoint pathway. In mammals, a variety of stress signals trigger the activation of CHK2 directly or indirectly through two related kinases ataxia telangiectasia mutated (ATM) and Rad3-related kinase (ATR; Hurley and Bunz, 2007) . Upon sensing the damage signals, ATM and ATR phosphorylate CHK2 on Thr68, which then leads to activation of CHK2. Once activated, CHK2 phosphorylates its downstream targets such as p53, Cdc25 and FOXM1, leading to growth arrest, apoptosis, or DNA repair (Iliakis et al., 2003; Antoni et al., 2007) .
TTK/hMps1/PYT is a human homolog of the yeast Mps1 family of protein kinases that are highly expressed in proliferating cells (Mills et al., 1992; Lindberg et al., 1993; Winey and Huneycutt, 2002) . It was first discovered through screening expression libraries with antiphosphotyrosine antibodies, and later shown to be a dual specificity protein kinase that phosphorylates tyrosine or serine/threonine residues (Mills et al., 1992) . TTK/hMps1 is a cell cycle-regulated kinase that displays maximum expression and activity in the M phase (Hogg et al., 1994) . The Mps1 family of kinases has been described in several other species including mouse (esk/mMps1; Douville et al., 1992) , S. cerevisiae (Mps1p; Winey et al., 1991) , S. pombe (Mph1p; He et al., 1998) , Xenopus laevis (xMps1; Abrieu et al., 2001) , zebrafish (mps1/ncp; Poss et al., 2002) and Drosophila (Mps1; Fischer et al., 2004) . In budding yeast (S. cerevisiae), this kinase is required for spindle pole duplication and spindle assembly checkpoint, whereas in mammals, although involved in spindle checkpoint, the kinase is thought to be involved in centrosome duplication, although this is debated (Weiss and Winey, 1996; Fisk and Winey, 2001 ; Stucke et al., 2002; Fisk et al., 2003) . During mitosis, Mps1 localizes to kinetochores and is required for proper chromosome alignment and segregation as well as the recruitment of other mitotic checkpoint proteins in the event of unattached chromosome or uneven tension at the kinetochores (Abrieu et al., 2001; Stucke et al., 2004; Vigneron et al., 2004; Jelluma et al., 2008) . The list of Mps1 functions has been expanded recently to include meiosis (Straight et al., 2000; Poss et al., 2004) , cytokinesis (Fisk et al., 2004) , development (Poss et al., 2002) and the response to DNA damage (Wei et al., 2005) .
In our previous report (Wei et al., 2005) , we demonstrated the physical interaction between TTK/ hMps1 and CHK2, and we established a functional relationship between the two proteins. Like ATM and ATR, TTK/hMps1 phosphorylates CHK2 at Thr68. Downregulation of endogenous TTK/hMps1/hMps1 by small interfering RNA (siRNA) or dominant-negative competition by overexpression of a kinase-defective TTK/hMps1 mutant compromises DNA damage-induced CHK2 Thr68 phosphorylation, and results in defective cell cycle arrest (Wei et al., 2005) . These results suggest that TTK/hMps1, like ATM, functions upstream of CHK2 in the response to genotoxic assaults. Many questions remain unanswered. For example, if TTK/hMps1 plays the role of a CHK2 activator, the mechanism underlying the activation of TTK/hMps1/ hMps1 or its induction by DNA damage becomes an imminent issue to resolve. Here we describe our efforts to address this issue. We present evidence that TTK/ hMps1 is induced by DNA damage in normal human fibroblasts and that such response is under reciprocal regulation by CHK2 phosphorylation at one critical residue, Thr288, in the N-terminal domain of TTK/ hMps1.
Result
Induction of TTK/hMps1 after DNA damage requires CHK2 In an attempt to investigate how TTK/hMps1 is regulated by DNA damage, we examined the levels of TTK/hMps1 before and after ionizing radiation (IR) in normal human fibroblasts, IMR90 and MRC5 cells (Figures 1a and b) . In these cells, TTK/hMps1 was transiently increased between 1 and 4 h after IR in IMR90 and between 0.5 and 3 h after IR in MRC5, at which times CHK2 Thr68 phosphorylation was also induced. A similar increase was observed in IMR90 after camptothecin treatment (Figure 1c) , except that the response lasted longer. The ATM-CHK2 pathway mediates the checkpoint response after IR (Hurley and Bunz, 2007) . To investigate the possibility of reciprocal regulation of TTK/hMps1 by CHK2, CHK2 in MRC5 was downregulated with siRNA before irradiation. As demonstrated in Figure 1d , whereas TTK/hMps1 was induced by IR in control siRNA-transfected cells, its levels remained unchanged in CHK2-ablated cells, suggesting that CHK2 is required for a proper response of TTK/hMps1 to radiation damage.
Increased expression and autophosphorylation of TTK/hMps1 upon coexpression of CHK2 in 293T cells To dissect the mechanisms underlying the DNA damage-induced increase in TTK/hMps1 expression, plasmids expressing HA-tagged TTK/hMps1 and myctagged CHK2 were cotransfected into 293T cells. Coexpression of wild type (WT) but not kinase deficient (KD) myc-CHK2 markedly increases HA-TTK/hMps1, regardless of whether the latter was WT or KD ( Figure 2a ). Such increase was partly contributed by increased autophosphorylation of WT TTK/hMps1. This was evidenced by a significant increase in a slower migrating, hyperphosphorylated form, which could be reduced to the faster migrating form by l-phosphatase treatment (Figure 2b ). These results are consistent with our observations on endogenous proteins (Figure 1 ) and suggest the existence of a positive regulatory role of CHK2 on TTK/hMps1.
To determine whether the increase was a result of stabilization of the TTK/hMps1 protein by CHK2, cycloheximide (CHX) was added in the coexpression experiment to examine the half-life of TTK/hMps1. In the presence of CHX, which inhibits de novo protein synthesis, transfected TTK/hMps1 was more stable when coexpressed with WT CHK2 than with KD CHK2, indicating that the half-life of TTK/hMps1 was significantly shorter when CHK2 was compromised (Figures 2c and d) . To exclude the possibility that the observation might be an artifact from overexpression, we also examined the stability of endogenous TTK with or without CHK2 ablation after IR. Similarly, the halflife of endogenous TTK/hMps1 in CHK2-knockdown MRC5 cells was also reduced, from about 6 h in control siRNA-transfected cells to 3 h in CHK2-ablated cells (Figures 2e and f) . Taken together, these results demonstrate that DNA damage induces stabilization of TTK/hMps1 and that this effect is mediated through CHK2.
CHK2 SCD and FHA domains, in addition to the kinase activity, are essential in the induction of TTK/hMps1 To identify the regions in CHK2 that are required to induce TTK/hMps1, several CHK2 mutants were made (Figure 3a) , all with reported compromised CHK2 activity in vitro (Xu et al., 2002; Figure 3a) . These mutants and WT CHK2 were cotransfected with HA-TTK/hMps1 into 293T cells, and the lysates were analysed by western blotting. In contrast to WT CHK2, neither the forkhead-associated (FHA) domain deletion mutant (DFHA, amino acids 76-213 deleted) nor the SQ/TQ cluster domain (SCD) deletion mutant (DSCD, amino acids 19-75 deleted) was capable of inducing TTK/hMps1 (Figure 3b, lanes 1-9) . A CHK2 mutant with Thr68 changed to Ala-induced TTK/ hMps1 at reduced levels ( Figure 3b, lanes 10-12) . To seek correlation with their kinase activity, myc-tagged WT CHK2 or mutants were immunoprecipitated from transfected 293T cells, and the kinase reactions were performed in vitro using recombinant GST-Cdc25A as the substrate. Unexpectedly, although DFHA mutant was largely defective in phosphorylating Cdc25A, the DSCD mutant was only slightly defective. In addition, the immunoprecipitated T68A mutant phosphorylated the substrate and autophosphorylated almost as well as did WT CHK2 (Figure 3c ). This result indicates that the kinase activity of CHK2, although required, is not the only determinant for inducing TTK/hMps1.
Other factors such as direct protein-protein interaction were examined further by an in vitro GST pulldown assay using GST or GST-TTK/hMps1 fusion and recombinant purified His-tagged WT or mutant CHK2 (KD, DFHA, DSCD). Results indicated that full-length CHK2 KD but not WT could bind TTK/hMps1 (Figure 3d ). In contrast, neither DFHA nor DSCD could bind, suggesting that both the FHA and SCD domains are required for the interaction. Indeed, a recombinant protein harboring these two domains (SCD þ FHA, Figure 3d ) was able to interact with TTK/hMps1.
The inability of the recombinant WT CHK2 to bind TTK/hMps1 was intriguing, and the possibility that this may be because of its autophosphorylation in bacteria was further explored. Indeed, after it was treated with l-phosphatase, it now became capable of interacting with GST-TTK/hMps1 almost as well as the KD mutant ( Figure 3e ).
On the basis of these analyses, we conclude that both the kinase activity and protein-protein interaction are required for CHK2 to induce TTK/hMps1 ( Figure 3d The N-terminal domain of TTK/hMps1 is responsible for the induction by CHK2 To identify the region in TTK/hMps1 that responds to CHK2, we constructed two TTK/hMps1 truncation mutants: one encompassing amino acids 1-386 (TTKN) and the other harboring amino acids 387-857 (TTKC). Similar to WT TTK/hMps1, the level of TTKN (1-386) was increased significantly by WT CHK2 but not by CHK2KD ( Figure 4a , lanes 1-3 and 7-9). In contrast, the TTKC mutant was not induced (Figure 4a , lanes 4-6). We further divided the TTKN (amino acids 1-386) mutant into two domains: one containing amino acids 1-193 and the other containing amino acids 194-386. The construct was able to respond to CHK2, whereas the TTKN (1-193) construct behaved similarly to TTKC and remained inert to CHK2 (Figure 4b ). The inability of to respond to CHK2 was not because of defective translation, because all constructs were driven by the same translation initiation sequence and were N-terminally tagged with the same HA epitope as the WT construct. Furthermore, both constructs, as well as WT TTK/hMps1, gave rise to products of the expected sizes in the in vitro reticulocyte translation system (Supplementary Figure S1) . However, were expressed consistently at levels Figure 1 CHK2-dependent induction of TTK/hMps1 by DNA damage in normal human fibroblasts, MRC5 and IMR90. Cells growing in the exponential phase were irradiated with 4 Gy of X-ray (a, b) or treated with 0.5 mM camptothecin (CPT; c), and collected at the time points indicated. Lysates were examined by SDS-polyacrylamide gel electrophoresis (PAGE) followed by western blotting using the indicated antibodies. (d) TTK/hMps1 induction by ionizing radiation (IR) is dependent on CHK2. Normal human fibroblasts, MRC5, were transfected with control small interfering RNA (siRNA) or CHK2-targeting siRNA for about 40 h and then treated with IR. Cells were harvested at 1 and 2 h after irradiation, and the total proteins were analysed as described above.
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Y-H Yeh et al lower than the WT construct (Supplementary Figure  S1) , perhaps reflecting the intrinsic instability of these two truncated proteins.
Mutation of TTK/hMps1 Thr288 to Ala mitigates CHK2-mediated TTK/hMps1 stabilization Whether can be phosphorylated by CHK2 and therefore be stabilized was investigated using an in vitro kinase assay with bacteria expressed, purified His-CHK2 as the kinase and recombinant as the substrate. As demonstrated in Figure 4c , was phosphorylated efficiently by CHK2 in a time-dependent manner. We then subjected the products of the in vitro kinase reaction to trypsin digestion, followed by liquid chromatography and tandem mass spectrometry to identify the phosphorylated amino-acid residues. As a result, Ser281, Thr288 and Ser291 were identified as the probable sites of phosphorylation. Figure 4d illustrates one analysis identifying the Ser281 and Thr288 sites. Ser281 and Thr288 were then mutated to Ala in the context of , and their roles in the response to CHK2 were examined by cotransfection experiments using 293T cells. Compared with the WT construct, the S281A mutant was less inducible, and the T288A mutant was the least induced, by CHK2 (Figure 4e ). In the context of the full-length TTK/ hMps1 protein, however, only the T288A mutant showed diminished induction by CHK2 (Figure 4f ). The level of induction with the S291A mutant was indistinguishable from that of the WT (data not shown). Consistently, the half-life of the T288A mutant was significantly shorter than that of the WT when they were coexpressed with CHK2 (Figure 4g ). These results suggest that Thr288 is the critical CHK2 phosphorylation Lysates coexpressing WT TTK/hMps1 and WT CHK2 were treated with l-phosphatase in the presence (lane 3) or absence (lane 2) of the inhibitor orthovanadate. The slower migrating form of TTK/hMps1 was converted to a faster migrating form, an indication of protein phosphorylation. (c) TTK/hMps1 is more stable when cotransfected with WT than with KD CHK2. Transfection experiments were performed in 293T cells with HA-TTK and myc-CHK2. Cycloheximide (CHX) was added at a final concentration of 20 mg/ml. Levels of TTK/hMps1 from three experiments were quantified and normalized to those of actin and shown in (d). (e) The half-life of TTK/hMps1 in ionizing radiation (IR)-treated, CHK2-depleted cells is reduced. MRC5 cells were transfected with control or chk2 small interfering RNA (siRNA), and irradiated with IR 40 h after transfection. One hour after IR, CHX was added, and cells were collected 2, 4 or 6 h later. The results from three experiments were quantified and shown in (f).
TTK/hMps1 as a CHK2 substrate Y-H Yeh et al site that plays an important role in CHK2-mediated TTK/hMps1 stabilization.
As the level of induction is at least partly attributable to TTK/hMps1 autophosphorylation (Figures 2a and  b) , we next compared the kinase activity of the T288A mutant and WT. In the in vitro kinase assay, the T288A mutant was fully active in phosphorylating the substrates, His-p53 and CHK2KD (Figure 4h ), and at times, performed better than the WT. Therefore, the inability to be stabilized by CHK2 cannot be attributed to its intrinsic kinase activity. Furthermore, in the GST pull-down assay, the T288A mutant interacted with CHK2 almost as well as the WT construct (Figure 4i ). We conclude that the T288A mutant is intrinsically less stable, most likely because of the absence of a critical CHK2 phosphorylation site, Thr288.
Phosphorylation at TTK/hMps1 Thr288 is enhanced by CHK2 in vitro and in vivo after IR As Thr288 phosphorylation was identified through in vitro assay, whether it is a physiological site then becomes a critical issue. To determine if Thr288 is a Lysates from (b) were immunoprecipitated with anti-myc, and the activity of CHK2 in the immunoprecipitate was assessed by an in vitro kinase assay using GST-Cdc25A (amino acids 101-140) as the substrate. (d) TTK/hMps1-CHK2 interaction requires the FHA and the SCD domains of CHK2. GST pull-down assays were performed with the indicated purified His-tagged CHK2 proteins and either GST or GST-TTK. After washing, bound proteins were analysed on SDS-polyacrylamide gel electrophoresis (PAGE) followed by western blotting using anti-His. GST proteins were detected by Ponceau S stain. (e) Phosphorylation of CHK2 interferes with the interaction with TTK/hMps1. Bacteria-expressed, His-tagged WT CHK2 was first treated with l-phosphatase then used in a GST pulldown assay as described in (d). Phosphatase treatment enhanced the interaction between WT CHK2 and TTK/hMps1 to the level comparable to that seen with kinase-defective (KD) CHK2.
TTK/hMps1 as a CHK2 substrate Y-H Yeh et al genuine in vivo CHK2 phosphorylation site, we generated a phospho-Thr288-specific antibody by immunizing rabbits with a synthetic phosphopeptide carrying phosphorylation at Thr288. As shown in Figure 5a , the antibody recognized WT TTK/hMps1 but not the T288A mutant immunoprecipitated from transfected 293T cells (Figure 5a, lanes 3-8) . The signal was enhanced when coexpressed with WT CHK2, whereas it was reduced in the presence of KD CHK2 (Figure 5a , lanes 3-5). In addition, the antibody did not recognize the GST-TKN (amino acids 268-308) fusion protein from bacteria unless it was coexpressed with WT but not with KD CHK2 (Figure 5b ). Taken together, these data indicate that the antibody is phopho-Thr288-specific and that CHK2 can phosphorylate this site in vivo.
We examined further whether Thr288 phosphorylation is inducible by DNA damage in cells. Because TTK/hMps1 also autophosphorylated at Thr288, at least when expressed in Escherichia coli (data not shown), we investigated the DNA damage effect in G 1 cells where CHK2 is functional and the kinase activity of TTK/hMps1 is minimal (Hogg et al., 1994) . TTK/ hMps1 was first immunoprecipitated from G 1 -synchronized HeLa cells treated with or without IR, followed by western analysis using the phopho-Thr288-specific antibody. Increased Thr288 phosphorylation was detected between 30 and 60 min after IR, and the signal decreased after 90 min in G 1 phase HeLa cells (Figure 5c ). Increased Thr288 phosphorylation was also observed in G 1 -synchronized normal human fibroblast IMR90 as revealed by the pT288/TTK ratios (Figure 5d ). Phosphorylation was enhanced by increasing doses of IR up to 4 Gy (Figure 5e ). In both of these cells, the induction was either abolished (Figure 5c ) or delayed (Figure 5d ) when cells were pretreated with CHK2 inhibitor before IR, indicating that CHK2 is responsible for the increase or induction after IR. Similarly, caffeine, which inhibits ATM-CHK2 signaling, also dampened the induction in G 1 phase HeLa cells (Supplementary Figure S2) . As a positive control, BRCA1 Ser988 phosphorylation, a CHK2-specific event (Lee et al., 2000) , was similarly deregulated as the phosphorylation at TTK Thr288 (Figure 5c ; Supplementary Figure S2 ), indicating that indeed CHK2 was effectively inhibited in these assays. We noted that the basal phosphorylation at TTK Thr288 and at BRCA1 Ser988 was enhanced upon treatment either with CHK2 inhibitor (Figures 5c and d) or with caffeine (Supplementary Figure S2) , suggesting that another kinase with similar substrate specificity might have been activated when CHK2 function was compromised.
Many checkpoint proteins, including CHK2, form phosphorylation-specific nuclear foci upon DNA damage (Ward et al., 2001) . After IR, phospho-Thr288 foci were also detected in the nuclei by immunofluorescence microscopy (Figure 5f ). The number and intensity of the foci increased significantly 30 min after IR, and these colocalized partially with g-H2AX. The foci were reduced by CHK2 inhibition, indicating that the kinase activity of CHK2 was responsible for the increase after IR (Figure 5g ).
Taken together, these results demonstrate that TTK/ hMps1 Thr288 is a CHK2 target site after IR.
The TTK/hMps1 Thr288 to Ala mutant (T288A) is defective in G 2 /M checkpoint control Because TTK/hMps1 is required for proper activation of CHK2 in the G 2 /M checkpoint (Wei et al., 2005) and, as demonstrated above, CHK2 may in turn control the stability of TTK/hMps1, we wondered whether this feedback control is essential in the G 2 /M arrest induced by IR. To address this issue, we first established Tet-off cell lines that inducibly express HA-tagged, siRNAresistant WT TTK/hMps1 or the T288A mutant. As depicted in Figure 6a , these cells expressed comparable amounts of HA-TTK (WT or T288A) upon withdrawal of doxycycline (Doxy). Following siRNA-mediated depletion of endogenous TTK/hMps1, the response of these cells to IR was analysed by flow cytometry. Ablation of endogenous TTK/hMps1 led to compromised G 2 /M arrest after IR (Wei et al., 2005; Figures 6b and c, upper rows). However, whereas the induction of RNAi-resistant WT TTK/hMps1 could compensate for the lost endogenous protein and increased the G 2 /G 1 ratio by 67%, the T288A mutant could do so by only 16% (Figures 6b and c, right columns) . Cdc2 Tyr15 phosphorylation, which accumulates in G 2 /M-arrested cells, was higher in WT than in T288A cells (Figure 6d ). In agreement, in another pair of cell lines, cyclin B, which accumulates in G 2 /M-arrested cells, was also higher in WT than in T288A cells (Supplementary Figure S3) . Of note, the CHK2 level was reproducibly lower in T288A cells than in WT cells after IR. The molecular basis of such reduction remains unclear. These observations were reproduced in additional clones (Supplementary Figure S3) , indicating that the defect was not a result of clonal selection. We conclude that the feedback phosphorylation of TTK/hMps1 Thr288 by CHK2 is important not only for maintaining the stability of TTK/hMps1, but also for proper G 2 /M arrest after IR.
As TTK/hMps1 was shown to be required for proper mitotic progression (Fisk et al., 2003) , whether the feedback regulation would affect long term cell survival was assessed by clonogenic assay. Consistent with the previous report (Fisk et al., 2003) , knockdown of TTK severely hampered cell survival as revealed by the numbers of colonies formed after 2 weeks of culture (Figure 6e ). This defect was rescued by reexpression of WT but not T288A TTK in the Tet-off cells (Figure 6e) , suggesting that the CHK2-TTK feedback control and TTK Thr288 phosphorylation are important for cell survival.
Discussion
It is widely accepted that members of the PI3K-related family of kinases, such as ATM and ATR, act as initiating kinases and are responsible for the triggering of the DNA damage response (DDR) in response to TTK/hMps1 as a CHK2 substrate Y-H Yeh et al various types of stress. Despite this consensus, we have demonstrated previously the involvement of an unrelated kinase TTK/hMps1 (Wei et al., 2005) . Indeed, TTK/hMps1, known as a mitotic checkpoint kinase, interacts with and activates CHK2 in DDR (Wei et al., 2005) . In this report, we present evidence that TTK/ hMps1, in addition to its role in centrosome duplication and spindle assembly checkpoint, can respond to DNA damage. Our data also show that this response requires CHK2 and is mediated through phosphorylation of Thr288. Upon DNA damage, TTK/hMps1 phosphorylates CHK2 at Thr68 (Wei et al., 2005) , and, as shown in this study, the activated CHK2 in turn phosphorylates TTK/hMps1 at Thr288 and stabilizes the kinase, thus forming a positive regulatory loop.
As demonstrated in this report, this relationship between TTK/hMps1 and CHK2 requires not only the kinase activity of CHK2 but also the interaction between the two proteins. Peculiarly, bacteria-expressed CHK2 KD but not WT binds TTK/hMps1 (Figure 3d ). Kinases are known to autophosphorylate themselves when overproduced in bacteria. Consistently, treating WT CHK2 with phosphatase restored its interaction with TTK (Figure 3e) , suggesting that the binding is in fact regulated by the phosphorylation state of CHK2. One can imagine that, once activated by DNA damage, autophosphorylation of CHK2 ensues; this then serves as a means to downregulate its interaction with TTK/ hMps1 and to turn off the DDR of TTK/hMps1. The transient nature of the pT288 damage foci (Figure 5f ) seems to support this hypothesis. A definitive view of the regulation may await side-by-side comparison of the kinetics of TTK Thr288 phosphorylation and the various phosphorylation events on CHK2.
The importance of such feedback regulation was further revealed in cells where endogenous WT TTK/ hMps1 was replaced with a mutant that cannot be phosphorylated at Thr288 (T288A). Although the mutant possesses an intrinsic kinase activity comparable to that of the WT (Figure 4h) , it is defective in the proper maintenance of G 2 /M arrest after IR. Intriguingly, a marked reduction in CHK2 was also observed in these T288A cells after IR, suggesting that Thr288 phosphorylation may regulate CHK2 in some way. Several possibilities may account for the decrease in CHK2. One possible explanation is that T288A is less able to interact with and phosphorylate CHK2 at Thr68 in vivo, which is unlikely in light of the results presented in Figures 4h, i and 6d . Another possibility is that T288A may not localize properly, for example to the damage foci, or that its localization may be poorly maintained because of the lack of phosphorylation at Thr288. If so, then the next question is why and how, under that situation, CHK2 is dysregulated. Further investigation is needed to unravel the underlying mechanisms.
Many kinases have been reported to regulate various activities of Mps1. For example, MAPK regulates kinetochore localization of Mps1 in Xenopus extract (Zhao and Chen, 2006) . Cdc28 of S. cerevisiae phosphorylates Mps1 on Thr28 to mediate spindle pole duplication (Jaspersen et al., 2004) . Likewise, murine Cdk2 activity is required for mMps1 stability and phosphorylates mMps1 in vitro (Fisk and Winey, 2001 ). In addition, autophosphorylation of TTK/hMps1 at Thr676 enhances the kinase activity (Mattison et al., 2007) and is required for the spindle checkpoint (Kang et al., 2007) . Notably, in addition to CHK2, two other kinases are also implicated in regulating the stability of TTK/hMps1. Cdk2/Cyclin A regulates the stability of hMps1 at the centrosome by phosphorylating Thr468 (Kasbek et al., 2007) ; and oncogenic B-Raf stabilizes hMps1 through ERK (Cui and Guadagno, 2008) , although the responsible phosphorylation site has not been identified. How these phosphorylation events lead to stabilization of hMps1 is still unclear. Although Cdk2-specific siRNA-mediated downregulation of hMps1 at the centrosome is reversed by the proteasome inhibitor MG115, levels of whole cell hMps1 are not altered significantly by either treatment (Kasbek et al., 2007) . Similarly in our study, the effect of CHK2 knockdown on the stability of hMps1 was not rescued by the proteasome inhibitor MG132, and treatment of cells with MG132 did not appear to affect the level of hMps1 (data not shown). Collectively, these observations imply that the stability of hMps1, except at the centrosome, is regulated by mechanisms other than proteasome-mediated degradation. On a related note, we were unable to observe the DNA damage-induced increase in hMps1 in several cancer cell lines, unless hMps1 was first downregulated by siRNA (data not shown) or when cells were enriched in G 1 phase by synchronization (Figure 5c ). The cause for this is unclear, but we suspect that this may relate to oncogenic mutation (for example, B-Raf as mentioned above) or elevated Cdk activity observed frequently in tumors (Enders and Maude, 2006; de Ca´rcer et al., 2007) . It is Figure 4 The effect of CHK2 on TTK/hMps1 is mediated through phosphorylation by CHK2 at Thr288 in the N-terminal domain of TTK/hMps1. (a) The N-terminal domain of TTK/hMps1 is responsible for CHK2-dependent induction. HA-TTK full-length or the N-(amino acids 1-386) or the C-(amino acids 387-857) domain was coexpressed with myc-CHK2 in 293T cells, and the level of proteins was examined by western blotting using the antibodies indicated. (b) A domain encompassing amino acids 194-386 of TTK/ hMps1 is responsible for the induction by CHK2. The N terminus of TTK/hMps1 was divided further at amino acid 193 into two regions, and each was coexpressed with myc-CHK2 as in (a). Only the C-terminal region responded to CHK2 in the coexpression assay. (c) CHK2 phosphorylates . The in vitro kinase assay was conducted with purified recombinant His-tagged proteins as indicated, and phosphorylation was detected by autoradiography. (d) Mass spectrometry showing the identification of a fragment that was doubly phosphorylated at Ser281 and Thr288. (e, f) Mutation of TTK/hMps1 at Thr288 but not Ser281 to Ala mitigates CHK2-mediated TTK/hMps1 stabilization. 293T cells were transfected with myc-tagged CHK2 and HAtagged TTKN (amino acids 194-290; e) or full-length TTK (f) carrying an Ala substitution at Ser281 or Thr288. Lysates were prepared 40 h after transfection and analysed by western blotting for expression using the antibodies indicated. (g) The TTK/hMps1 T288A mutant is less stable than wild type (WT). Transfection of 293T cells was conducted as described above and the half-lives of proteins were measured by the addition of cycloheximide (CHX). (h) The kinase activity of the TTK T288A mutant is comparable to that of WT. The in vitro kinase assay was performed with recombinant purified GST-TTK WT or T288A using His-CHK2KD or His-p53 as the substrate. (i) TTK/hMps1 T288A binds CHK2 as efficiently as does WT TTK/hMps1. The GST pull-down assay was performed as described in Figure 3d using GST, GST-TTK WT, or T288A and His-CHK2. The pull-down proteins were detected by western using an anti-His antibody.
TTK/hMps1 as a CHK2 substrate Y-H Yeh et al possible that, as a result of these alterations, the Mps1 kinase is fairly stable in cancer cells, and additional phosphorylation by CHK2, as would occur upon DNA damage, may be unable to cause further discernible changes. Nevertheless, our results also indicate that, in addition to regulating hMps1 stability, CHK2-mediated phosphorylation at Thr288 may carry an additional function because replacing the endogenous Mps1 with a kinase-competent T288A mutant in HeLa cells could not restore full G 2 arrest (Figure 6c ). Further investigation on the significance of Thr288 phosphorylation is warranted to reveal its other faces of regulation.
Figure 5 DNA damage-induced phosphorylation at Thr288 is dependent on CHK2 in vivo. (a) TTK/hMps1 Thr288 phosphorylation is enhanced by wild-type (WT) CHK2 but dampened by kinase-defective (KD) CHK2 in cotransfected 293T cells. HA-TTK was first immunoprecipitated from cell lysates, and the level of Thr288 phosphorylation was detected by western blotting using phospho-Thr288-specific antibody (pT288). Note that the antibody did not recognize the T288A mutant, demonstrating the specificity of the antibody. (b) CHK2 phosphorylates TTK at Thr288 in vivo. Flag-tagged CHK2, WT or KD, was coexpressed in Escherichia coli with GST or GST fused to TTK amino acids 268-308 (GST-TKN). Lysates were then prepared, and level of Thr288 phosphorylation was determined by western analysis following GST pull-down. Three different amounts of lysates were loaded for the comparison. (c) CHK2-dependent induction of Thr288 phosphorylation in G 1 -synchronized HeLa cells after ionizing radiation (IR). HeLa cells were arrested in prometaphase with nocodazole (50 ng/ ml) and irradiated with X-rays 7 h after release when most of cells were in G 1 , with or without pretreatment with 2 mM of CHK2 inhibitor II (Calbiochem) for 1 h. Cell extracts were prepared at the indicated times, and Thr288 phosphorylation was examined by first immunoprecipitation with anti-TTK followed by western analysis with the phospho-Thr288-specific antibody (pT288). BRCA1 Ser988 phosphorylation, a CHK2-specific event, was used as a control for CHK2 inhibition. (d) Increase in Thr288 phosphorylation in G 1 -synchronized IMR90 cells. Near confluent IMR90 cells were starved for 3 days before they were replated in normal medium. Seven hours after replating, cells were irradiated with IR (8 Gy), and whole cell lysates were prepared for western analysis using pT288 antibody. (e) Dosedependent increase in Thr288 phosphorylation. G 1 -synchronized IMR90 cells were irradiated with increasing doses of IR. Cell lysates were collected 1 h after IR and analysed by western blotting using pT288 antibody. (f) Phospho-Thr288 damage foci are induced by IR. HeLa cells enriched in G 1 were irradiated with X-rays (8 Gy), fixed at the indicated time after brief permeabilization and then processed for indirect immunofluorescence microscopy using pT288 and g-H2AX antibodies. The nuclei were stained with 4 0 -6-diamidino-2-phenylindole (DAPI). (g) Phospho-Thr288 damage foci are diminished upon inhibition of CHK2. Cells as described in (f) were pretreated with CHK2 inhibitor II for 1 h before IR, then processed for immunofluorescence microscopy. Foci at 30 min after IR were compared.
Materials and methods

Cell culture and treatments
To grow tetracycline-repressible stable HeLa cells expressing HA-TTK/hMps1, G418 (300 mg/ml), puromycin (0.4 mg/ml) and Doxy (1 mg/ml) were included in the medium. IR treatment was performed as described previously (Wei et al., 2005) .
Cell transfection and western blot analysis 293T and HeLa cells were transfected by calcium phosphate precipitation and Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), respectively. Lysis of cells and western analysis were conducted as described previously (Wei et al., 2005) . Antibodies against TTK/hMps1 (sc-540), p-CHK2 (Thr68; sc-16297-R), p-BRCA1 (Ser988; sc-12888-R), myc (sc-40), and GST (sc-138) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal antibody against CHK2 (K0087) was purchased from MBL (Nagoya, Japan), and polyclonal antiactin antibody (A2066) was from Sigma (St Louis, MO, USA).
RNA interference
The sequences targeted by TTK/hMps1 and CHK2 siRNA are 5 0 -tgaacaaagtgagagacat-3 0 and 5 0 -aatgtgtgaatgacaactact-3 0 , respectively. All siRNAs were synthesized by and purchased from Qiagen (Valencia, CA, USA). Transfection of siRNA 
Plasmid construction
Plasmids for mammalian expression of the myc-tagged WT and KD (D347A) CHK2 were described previously (Shieh et al., 2000) . DFHA (amino acids 77-213 deleted) was generated by removing an internal Bsu36I fragment from the cDNA followed by religation. T68A and DSCD (amino acids 19-75 deleted) mutants were constructed by plasmid-based site-directed mutagenesis (Wang et al., 2006) . The TTK/hMps1 truncation mutants were generated by PCR and cloned into pcDNA-HA for expression. The TTK/hMps1 S281A and T288A point mutants were made by PCR-based site-directed mutagenesis and confirmed by sequencing.
TTK/hMps1 siRNA-resistant constructs (TTK/hMps1-r) were made by introducing silent mutations within the TTK/ hMps1 siRNA-targeted region (nt 50-68; 5 0 -tgaacaaagtGAGA gacat-3 0 to 5 0 -tgaacaaagtACGCgacat-3 0 ) by PCR-based sitedirected mutagenesis.
The construct for E. coli expression of His-CHK2 SCD þ FHA (amino acids 19-175) was generated by PCR using appropriate primers and cloned into the KpnI and EcoRI sites of pRSET B (Invitrogen). For expression of GST-TTK/ hMps1 and His-TTKN (amino acids 194-386), the vectors pGEX-4T (Amersham Biosciences, Piscataway, NJ, USA) and pRSET (Invitrogen) were used, respectively, for cloning.
For coexpression of CHK2 and GST-TTKN (268-308) in E. coli, CHK2 was recloned into the SalI and NotI sites of pET29b (Novagen, Gibbstown, NJ, USA) and expressed as a C-terminal Flag-tagged protein.
Phospho-Thr288-specific antibody Rabbit polyclonal antiphospho-Thr288 antibody was raised against a phosphopeptide H-CDVKpTDDSV-OH conjugated to ovalbumin by LTK Biolaboratories (Touyuan, Taiwan). The antibody was purified by binding to phospho-Thr288 peptide, followed by passing the eluted antibodies through an unphosphorylated peptide column to remove those that cross-reacted with unphosphorylated epitopes. All peptides Figure 6 The TTK/hMps1 T288A mutant is compromised in restoring G 2 /M arrest in TTK-knockdown cells. (a) Expression of small interfering RNA (siRNA)-resistant HA-TTK/hMps1 in two of the stable HeLa cell lines wild type (WT)-r-9 and T288A-r-16 upon withdrawal of doxycycline (Doxy). These Tet-off cells were transfected with TTK siRNA in the presence or absence of Doxy, and irradiated 2 days later with X-rays (8 Gy; b, c). Cells were collected at the times indicated and processed for flow cytometry. Numbers indicate the G 2 /G 1 ratios. (d) Impaired accumulation of Cdc2 Tyr15 phosphorylation in cells expressing T288A-r. Tet-off cells were transfected with TTK siRNA in the absence of Doxy and processed as described in (b, c). Cells were lysed 14 h after irradiation and analysed by western blotting using the antibodies indicated. Nucleolin was used as a loading control. (e) Reexpression of WT TTK but not the T288A mutant rescued the survival of the TTK-ablated cells. Colony survival assays were performed with TTK siRNAtransfected WT-r-9 and T288A-r-16 cells in the presence or the absence of Doxy. Colonies from one representative assay were shown on the left. Results from three duplicated experiments were averaged and shown on the right.
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